Metastatic melanoma is challenging to manage. Although targeted-and immune therapies
have extended survival, most patients experience therapy resistance. The adaptability of …

Immune checkpoint inhibitors (ICIs) have changed perspectives for patients with cancer, but
come with severe immune-related adverse events (irAEs). To prevent fatality or chronicity …

Melanoma is one of the most aggressive malignancies of the skin. The genetic composition
of melanoma is complex and varies among different subtypes. With the aid of recent …

Cutaneous melanoma (CM) is a highly malignant tumor originating from melanocytes, and
its metastasis and recurrence are the major causes of death in CM patients. PANoptosis is a …

Immune checkpoint inhibitors (ICIs) have transformed the treatment of patients with
advanced cancers. However, the majority of patients do not respond or develop early …

PURPOSE To address the paucity of data in patients with historically poor outcomes, we
conducted the single-arm phase IIIb CheckMate 401 study to evaluate the safety and …

Background: Several studies indicate the level of pretreatment lactate dehydrogenase (LDH)
may be associated with the prognosis of patients receiving immune checkpoint inhibitors …

Real-world evidence plays an important role in the assessment of efficacy and safety of
novel therapies. The increasing use of immune checkpoint inhibitors (ICIs) in patients with …

Cancer, a significant threat to human lives, has been the target of research for several
decades. Although conventional therapies have drawbacks, such as side effects, low …

Background: Immune checkpoint inhibitors (ICIs) showed promising therapeutic efficacy on
melanoma. Neutrophil-to-lymphocyte ratio (NLR) and serum lactate dehydrogenase (LDH) …